Evicenter
MarkdownMedical informationP&T meetings
Ersodetug (RZ358)

Tumor hyperinsulinism

Manufacturer
Rezolute
Launch
Not announced
Last updated
140 sources

Clinical evidence

sunRIZE

65 evidence topics · 15 sources

Objective
Location and study date
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using weekly hypoglycemia events by self-monitored blood glucose as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Full analysis set

No evidence found.

Results
Participant disposition
Baseline characteristics
Demographics, background therapy, and baseline glycemia of the enrolled population
ParameterErsodetug 5 mg/kgErsodetug 10 mg/kgPlaceboOverall, including open-label arm
Number of participants“(N=18)”“(N=20)”“(N=17)”“(N=63)”
Age in years, mean (range)“3.4 (1-15 y)”“3.9 (5 mo to 9 y)”“4.0 (5 mo to 10 y)”“3.4 (3 mo to 15 y)”
Female, n (%)“8 (44%)”“10 (50%)”“7 (41%)”“31 (49%)”
Genetics, KATP / other or unknown, n (%)“13 (72%) / 5 (28%)”“11 (55%) / 9 (45%)”“15 (88%) / 2 (12%)”“47 (75%) / 16 (25%)”
Current standard of care therapy“17 (94%)”“18 (90%)”“17 (100%)”“60 (95%)”
Diazoxide, n (%)“9 (50%)”“11 (55%)”“5 (29%)”“26 (41%)”
Somatostatin analog, n (%)“10 (56%)”“11 (55%)”“14 (82%)”“46 (73%)”
Scheduled enteral tube feeding, n (%)“7 (39%)”“7 (35%)”“7 (41%)”“24 (38%)”
Two or more therapies, n (%)“8 (44%)”“9 (45%)”“8 (47%)”“29 (46%)”
Pancreatectomy, n (%)“2 (11%)”“3 (15%)”“2 (12%)”“8 (13%)”
Pre-study use of CGM, n (%)“8 (44%)”“11 (55%)”“9 (53%)”“32 (51%)”
Congenital HI-related hospitalizations in previous year, n (%)“6 (33%)”“12 (66%)”“10 (59%)”“32 (51%)”
Hypoglycemia events per week by SMBG, mean (range)“12.7 (5-42.0)”“13.4 (4-37)”“11.7 (3-22)”“12.6 (3-42)”
Percent time in hypoglycemia by CGM, mean (range)“23.1 (5-73)”“20.0 (6-71)”“13.0 (7-38)”“19.1 (5-73)”
HbA1c, mean % (range)“4.96 (3.9-5.9)”“5.01 (3.9-6.0)”“5.32 (4.2-6.2)”Not reported
Average glucose by SMBG, mean mg/dL“81”“82”“86”Not reported
Hypoglycemia Fear Survey worry score, mean“27.1”“28.2”“34.6”Not reported
Efficacy results
Health-related quality of life and patient-reported outcomes
Safety results
Study limitations
Summary
  • Population: sunRIZE enrolled participants with congenital hyperinsulinism aged 3 months to 45 years, a different disease and a younger population than adults with tumor hyperinsulinism, so its efficacy results are indirect evidence for this report. Its main relevance here is the safety data and its effect on the regulatory assessment.
  • Outcome: the trial did not meet its primary or key secondary endpoint. The favorable continuous glucose monitoring results at earlier time points and in the per protocol set are nominal, and the company's explanation of the result (self-monitored measures confounded by functional unblinding through real-time glucose monitoring) is its own interpretation.
  • Reporting: results are available only from company releases, filings, and congress slides, with no peer-reviewed publication. Sources differ on the number of discontinuations for hypersensitivity (2 serious reactions in the topline release; 3 participants in the congress slides; 4 early terminations in the January 2026 presentation), on the CGM result at 10 mg/kg (“approximate 25% reduction” against “-32%; p=0.30”), and on hypertrichosis (36% and about 35%). One baseline cell reads “12 (66%)” for 12 of 20 participants. The registry still lists an estimated enrollment of 56.
  • The open-label extension is ongoing, and its glycemic observations are described by the company as preliminary.